| Literature DB >> 31980117 |
Leah M Wilson1, Peter G Jacobs2, Jessica R Castle3.
Abstract
Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous. Automated insulin delivery systems can improve glucose control while reducing burden for people with diabetes. One approach to improve treatment outcomes is to incorporate the counter-regulatory hormone glucagon into the automated delivery system to help prevent the hypoglycemia that can be induced by the slow pharmacodynamics of insulin action. This article explores the advantages and disadvantages of incorporating glucagon into dual-hormone automated hormone delivery systems.Entities:
Keywords: Dual-hormone artificial pancreas; Glucagon; Hypoglycemia; Intranasal glucagon; Minidose glucagon; Type 1 diabetes
Mesh:
Substances:
Year: 2019 PMID: 31980117 PMCID: PMC7398489 DOI: 10.1016/j.ecl.2019.10.008
Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN: 0889-8529 Impact factor: 4.741